ONL Therapeutics’ primary focus is Fas-mediated signaling, initiated by the activation of the Fas receptor at the cell surface and implicated in a variety of diseases.
Fas-mediated signaling has traditionally been considered one of the body’s cornerstone mechanisms for activating cell death. Death of vital cells is a root cause of a host of diseases and conditions and has been specifically associated with many retinal diseases.
In addition to its close association with cell death, Fas can also play a role in regulating immune signaling and associated inflammation. This distinct function of Fas is becoming more widely understood and appreciated. Fas-mediated immune signaling can induce additional cell death, increase damage to the surrounding tissues, and worsen the initial injury from the disease.
Fas-mediated cell death and immune signaling have been implicated in the development and progression of many diseases and conditions. ONL and others have demonstrated vital roles for Fas in a wide range of retinal disease, including retinal detachment, dry and wet age-related macular degeneration, uveitis, diabetic retinopathy, glaucoma, and optic neuropathies.
Therefore, inhibition of Fas signaling at the receptor represents the most direct and upstream approach to preventing its negative impact. ONL believes that the therapeutic benefits of blocking Fas activation and its subsequent signaling may have immense and wide-ranging clinical value for retinal disease patients.
ONL believes that the therapeutic benefits of blocking Fas activation and its subsequent signaling may have immense and wide-ranging clinical value for retinal disease patients.